Table 2.

Relative organ weight for mice treated with UP601 in HFH-induced mouse obesity model

Group	Liver (%)	Fat deposit (%)
		Epididymal	Retroperitoneal	Peri-Renal	Mesenteric	Total
NC	3.39 ± 1.47	1.75 ± 0.33‡	0.44 ± 0.14‡	0.24 ± 0.10‡	0.81 ± 0.15‡	3.22 ± 0.67‡
HFF	3.17 ± 0.47	6.93 ± 1.06	1.69 ± 0.30	0.99 ± 0.20	2.76 ± 0.97	12.36 ± 1.17
ORI (40)	3.21 ± 0.12	5.75 ± 1.59	1.41 ± 0.38	0.65 ± 0.17†	1.58 ± 0.64*	9.38 ± 2.63*
UP601 (300)	2.83 ± 0.14	6.82 ± 0.64	1.68 ± 0.14	0.82 ± 0.17	1.99 ± 0.48	11.31 ± 0.92
UP601 (450)	2.96 ± 0.16	5.31 ± 1.04*	1.53 ± 0.29	0.55 ± 0.12‡	1.38 ± 0.24	8.76 ± 1.54‡
UP601 (600)	2.99 ± 0.17	1.57 ± 1.57†	0.42 ± 0.42*	0.12 ± 0.12‡	0.30 ± 0.30†	2.41 ± 2.41‡

HFF-induced obese C57BL/6J mice were treated with UP601 at oral doses of 300, 450 and 600 mg/kg for 7-weeks. Orlistat (ORI) at 40 mg/kg was used as a reference compound. Tissue collections were carried out at necropsy. NC Normal control + vehicle, HFF HFF + Vehicle, ORI HFF + orlistat, UP601 HFF + indicated concentrations of UP601 (mg/kg). * P ≤ 0.05 compared to HFF group; † P ≤ 0.001 compared to HFF group; ‡ P ≤ 0.0001 compared to HFF group